Jessika Kissling, MD
Obstetrics & Gynecology · Reading, PANPI 1487800306
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $260 of the $359 with a category attached, or 72.4%. 11 manufacturers reported payments, led by Astellas Pharma US Inc at 33.5% of the total. That places this record below the midpoint for obstetrics & gynecology clinicians in PA, where the typical reported total is $309.
Across 15 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$120
- Pfizer$42
- Axonics, Inc.$41
- Kowa Pharmaceuticals America, Inc.$32
- Organon$24
- AbbVie$21
- plus $78 from 5 others
What the payments were for
- Food & beverage$26072%
- Education$9928%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $120 |
| Pfizer | 2 | $42 |
| Axonics, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Organon | 1 | $24 |
| AbbVie | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Meditrina | 1 | $16 |
| Bayer | 1 | $15 |
| Merck | 1 | $15 |
| KCI USA, Inc. | 1 | $13 |
How this compares
$359 in reported general payments places this provider in the 50th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 63 | $3,322 |
| YuvafemEstradiol | 15 | $1,268 |
| ValacyclovirValacyclovir Hcl | 23 | $783 |
| Estradiol (Once Weekly)Estradiol | 11 | $733 |
| ProgesteroneProgesterone, Micronized | 26 | $678 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $453 |
| Clobetasol Propionate | 12 | $407 |
| Fluconazole | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Reading
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
- Barry JacobsonGlen Mills$302K
- Timothy GrubeFrackville$260K
- Russell StankiewiczLewisburg$202K
- Jamille Nagtalon-RamosPhiladelphia$183K
- Timothy DeimlingMechanicsburg$182K
- Gerald HarkinsMechanicsburg$140K
- Kirthik ParthasarathyWest Reading$103K
- Catherine ChappellPittsburgh$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.